NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 421
(Total Views: 197)
Posted On: 05/06/2022 5:26:51 PM
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-Nicotine Pouch Performance to Be Compared to That of Leading Brands
Lexaria Bioscience Corp. (NASDAQ: LEXX) is expected to begin dosing for the NIC-H22-1 human study this summer. “NIC-H22-1, a pharmacokinetic randomized, double-blinded, cross-over study involving 36 human participants, will compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands available to U.S. customers, namely ON! and Zyn,” a recent article reads. The human study NIC-H22-1 is expected to build on the successes of the company’s animal studies, which have proven the technology’s effectiveness in promoting faster absorption, higher peak absorption, and greater overall quantities of nicotine, on average, in the blood than concentration-matched control formulations. “In 2021, the company announced its oral nicotine absorption study, NIC-A21-1, revealing that DehydraTECH-oral nicotine delivery peaked in the bloodstream 10x to 20x faster than controls, and peak levels achieved were up to 10x higher than controls. ‘Performance gains of this magnitude could be of great significance in enabling the oral pouch product category to offer improved nicotine satiety and effectiveness, with a goal of one day rendering pulmonary administration practices like smoking and vaping as obsolete,’ Lexaria CEO Chris Bunka said of last year’s outstanding results.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. (NASDAQ: LEXX) is expected to begin dosing for the NIC-H22-1 human study this summer. “NIC-H22-1, a pharmacokinetic randomized, double-blinded, cross-over study involving 36 human participants, will compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands available to U.S. customers, namely ON! and Zyn,” a recent article reads. The human study NIC-H22-1 is expected to build on the successes of the company’s animal studies, which have proven the technology’s effectiveness in promoting faster absorption, higher peak absorption, and greater overall quantities of nicotine, on average, in the blood than concentration-matched control formulations. “In 2021, the company announced its oral nicotine absorption study, NIC-A21-1, revealing that DehydraTECH-oral nicotine delivery peaked in the bloodstream 10x to 20x faster than controls, and peak levels achieved were up to 10x higher than controls. ‘Performance gains of this magnitude could be of great significance in enabling the oral pouch product category to offer improved nicotine satiety and effectiveness, with a goal of one day rendering pulmonary administration practices like smoking and vaping as obsolete,’ Lexaria CEO Chris Bunka said of last year’s outstanding results.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)